Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06448026 · ClinicalTrials.gov registry record · Phase 2
Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).
A Phase 2 study of Locally Recurrent Oral Cavity Squamous Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT06448026 is a Phase 2 study of Locally Recurrent Oral Cavity Squamous Cell Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 17 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06448026, a Phase 2 study of Locally Recurrent Oral Cavity Squamous Cell Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if giving cemiplimab and cetuximab before salvage surgery can help to control recurrent oral cavity squamous cell carcinoma.
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG Cetuximab
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2027-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06448026
The ClinicalTrials.gov registry entry for NCT06448026 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Recurrent Oral Cavity Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT06448026 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06448026 about?
NCT06448026 is a clinical study titled "Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).". To learn if giving cemiplimab and cetuximab before salvage surgery can help to control recurrent oral cavity squamous cell carcinoma.
What is the current status of trial NCT06448026?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2024-11-21. Estimated completion is 2027-05-15.
What conditions does trial NCT06448026 study?
This clinical trial studies the following conditions: Locally Recurrent Oral Cavity Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06448026?
The interventions under investigation include: Cemiplimab (DRUG), Cetuximab (DRUG).
Who is sponsoring clinical trial NCT06448026?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06448026 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
RECRUITING · Phase 2
-
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.